Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Anti-CDH17 CAR-T Cells by UTC Therapeutics for Pancreatic Cancer: Likelihood of Approval
Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer. According to...
Data Insights
Anti-CDH17 CAR-T Cells by UTC Therapeutics for Colorectal Cancer: Likelihood of Approval
Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Colorectal Cancer. According to...